Zymeworks Appoints Chief People Officer
16 Outubro 2019 - 5:15PM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional therapeutics, today announced
the appointment of Kathryn O’Driscoll to the executive team as
Chief People Officer (CPO).
Ms. O'Driscoll brings over 20 years of experience as an
executive-level human resources leader across large global
organizations in the technology and non-profit sectors. In her new
role as Zymeworks’ CPO, she will be responsible for growing and
developing its highly diverse and skilled workforce.
"As Zymeworks becomes a later stage biotechnology company and
expands its operations across the United States and Canada, Kathy
will be instrumental in recruiting and supporting the very best
talent to further strengthen our innovative, patient-centric
culture,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO.
“She brings a wealth of experience building and managing innovative
teams rooted in a strong corporate culture at high-growth
organizations like Microsoft, PATH, and Snowflake, which will serve
our growing demands as we move closer to commercialization.”
Ms. O'Driscoll has held various senior people-centric roles at
Microsoft, including within the Server and Tools Business, which
consisted of more than 11,000 employees and generated $13 billion
in revenue. Most recently, she served as Vice President of People
at Snowflake, a top cloud computing company where she led the
development and implementation of people growth strategies and
operations worldwide. Formerly she was the Vice President and Chief
Human Resources Officer at PATH, an international leader in global
health innovation, where she led a human resources team that had
impact in over 50 countries.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody
currently in Phase 2 clinical development. Zymeworks’ second
clinical candidate, ZW49, is a bispecific antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of ZW25 with Zymeworks’ proprietary
ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep
preclinical pipeline in immuno-oncology and other therapeutic
areas. In addition, its therapeutic platforms are being leveraged
through strategic partnerships with nine biopharmaceutical
companies. For more information, visit www.zymeworks.com.
Cautionary Note Regarding Zymeworks’ Forward Looking
Statements
This press release includes “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this news release include
statements that relate to the anticipated growth and development of
Zymeworks’ workforce, expansion of operations across the United
States and Canada, move towards commercialization, and other
information that is not historical information. When used herein,
words such as “will”, “becomes”, believe”, “may”, and similar
expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations,
beliefs, plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon Zymeworks’ current expectations and
various assumptions. Zymeworks believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain. Zymeworks may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various factors, including, without
limitation, market conditions and the factors described under “Risk
Factors” in Zymeworks’ Quarterly Report on Form 10-Q for the three
month period ended June 30, 2019 (a copy of which may be obtained
at www.sec.gov and www.sedar.com). Consequently, forward-looking
statements should be regarded solely as Zymeworks’ current plans,
estimates and beliefs. You should not place undue reliance on
forward-looking statements. Zymeworks cannot guarantee future
results, events, levels of activity, performance, or achievements.
Zymeworks does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances, or to reflect the occurrences of unanticipated
events, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191016005640/en/
Zymeworks Inc.
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Tiffany Tolmie (604) 678-1388 ir@zymeworks.com
Media Inquiries: Kavita Shah, Ph.D. (604) 678-1388
info@zymeworks.com
Zymeworks (NYSE:ZYME)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Zymeworks (NYSE:ZYME)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024